Benralizumab for severe eosinophilic asthma
Bleecker ER, FitzGerald JM, Goldstein D
New England Journal of Medicine · 2016
This randomized controlled trial evaluates the intervention under study in relation to the primary clinical outcome. Includes 1,205 participants. Evidence level: Ia.
循证研究：Benralizumab治疗严重嗜酸粒细胞性哮喘
Key facts at a glance
- DOI
- 10.1056/NEJMoa1702000
- PMID
- 29241626
- Journal
- New England Journal of Medicine
- Year
- 2016
- Study type
- rct
- Evidence level
- Ia
- Sample size
- 1205
- Intervention
- Benralizumab 30mg/4-8周 vs 安慰剂
- Primary outcome
- 年急性加重率
- Open access
- false
Study Overview
This randomized controlled trial enrolled 1,205 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ia.
Abstract
"This randomized controlled trial enrolled 1,205 participants, investigating the effects of Benralizumab 30mg/4-8周 vs 安慰剂 on 年急性加重率.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy